1. Report Overview
1.1 Global Dermatological Drugs Market Overview
1.2 Overview of Findings
1.3 Structure of the Report
1.4 Global Dermatological Drugs Market Segmentation
1.5 Why You Should Read This Report
1.6 How This Report Delivers
1.7 Key Questions Answered by This Analytical Report
1.8 Who is This Report For?
1.9 Methodology
1.10 Associated Visiongain Reports
1.11 About Visiongain
2. Introduction to Dermatological Drugs
2.1 The Pharmaceutical Industry: A Brief Introduction
2.2 An Introduction to Dermatology
2.2.1 The Structure of Skin, Hair, and Nails
2.2.2 Hair and Nails
2.2.3 Sweat and Sebaceous Glands
2.2.4 Functions of the Skin
2.3 Common Skin Diseases
2.3.1 Acne: The Most Common Skin Disease
2.3.1.1 Acne: Epidemiology
2.3.1.2 Acne: Causes and Pathogenesis
2.3.1.3 Acne: Treatment
2.3.2 Dermatitis: Inflammation of the Skin
2.3.2.1 Atopic Dermatitis
2.3.2.2 Contact Dermatitis
2.3.2.3 Seborrhoeic Dermatitis
2.3.2.4 Nummular Dermatitis
2.3.2.5 Perioral Dermatitis
2.3.3 Psoriasis: A Complex Multi-Factorial Disease
2.3.4 Rosacea: Vascular Instability
2.3.5 Alopecia: Excessive Shedding of Hair
2.4 Skin Infections: A Serious Healthcare Threat
2.4.1 Bacterial Skin Infections
2.4.2 Fungal Skin Infections
2.4.3 Viral Skin Infections
2.5 Common Skin Treatments
2.5.1 Creams and Semisolid Emulsions
2.5.2 Ointments
2.5.3 Lotions
2.5.4 Solutions
2.5.5 Occlusive Therapy
2.5.6 Cleansing Agents
2.5.7 Powders and Hydrophilic Polymer
2.5.8 Anti-Infective Agents
2.5.9 Anti-Inflammatory Agents
2.6 Phases of Clinical Trials
2.7 Dermatological Drugs: Market Definition in this Report
3. Global Dermatological Drugs Market, by Drugs Class 2018-2028
3.1 The Global Dermatological Drugs Market: Market Overview
3.2 Categorisation of the Global Dermatological Drugs Market
3.3 The Global Dermatological Drugs Market in 2017
3.4 The Global Dermatological Drugs Market: Market Forecast 2018-2028
3.5 Changing Market Shares by Segment 2018-2028
4. The Psoriasis Drugs Market: Market Analysis and Forecast 2018-2028
4.1 Psoriasis Treatments: The Dominance of Biologics
4.1.1 Leading Products in the Psoriasis Drugs Market, 2017
4.2 Psoriasis: Market Trends and Developments, 2017
4.2.1 Biological Drugs in Psoriasis Treatment: A Brief Overview
4.2.2 Issues around Patent Protection, the Threat of Biosimilars and Pricing
4.2.3 Biosimilars and Interchangeables
4.2.3.1 Extrapolation of indications
4.2.3.2 Biosimilar interchangeability in the EU
4.2.3.3 Biosimilar guidance in the US
4.2.3.4 The Disadvantages of Biologics in Psoriasis Treatment
4.3 Psoriasis Drugs: Market Forecast 2018-2028
4.3.1 Psoriasis Drugs: Changing Market Shares by Leading Drugs 2018-2028
4.4 Leading Drugs Used in the Treatment of Psoriasis
4.4.1 Humira (adalimumab) - AbbVie
4.4.1.1 Humira: Historical Sales Analysis, 2010-2017
4.4.1.2 Humira: Sales Forecast 2018-2028
4.4.1.3 Future Prospects for Biosimilar Versions of Humira
4.4.2 Stelara (ustekinumab) – Johnson & Johnson
4.4.2.1 Stelara New Market Leader, Ahead of Humira
4.4.2.2 Stelara: Historical Sales Analysis, 2010-2017
4.4.2.3 Stelara: Sales Forecast 2018-2028
4.4.2.4 Intensifying Competition for Stelara
4.4.3 Enbrel (etanercept) - Amgen/ Pfizer/ Takeda
4.4.3.1 Enbrel: Co-Promotions and Marketing Rights
4.4.3.2 Enbrel: Historical Sales Analysis, 2009-2017
4.4.3.3 Enbrel: Patent Expiries and Potential Competition, 2018-2028
4.4.3.4 Patent Litigation with Sandoz Over Enbrel
4.4.3.5 Enbrel: Sales Forecast 2018-2028
4.4.3.6 Enbrel Auto-injector Pens: A Driver of Growth in Recent Years
4.4.3.7 Competition from Other Drugs
4.4.3.8 Biosimilar Competition for Enbrel
4.4.4 Remicade (infliximab) – Johnson & Johnson
4.4.4.1 Remicade: Historical Sales Analysis, 2009-2017
4.4.4.2 Remicade: Patent Expiries and Potential Competition, 2018-2028
4.4.4.3 Remicade: Sales Forecast 2018-2028
4.4.5 Taltz (ixekizumab) – Eli Lilly
4.4.5.1 Taltz: Sales Forecast 2018-2028
4.4.6 Otezla (apremilast) – Celgene
4.4.6.1 Otezla: Sales Forecast 2018-2028
4.4.7 Cosentyx (secukinumab) - Novartis
4.4.7.1 Cosentyx: Sales Forecast 2018-2028
4.4.8 Other Psoriasis Drugs
4.4.8.1 Cimzia (certolizumab) - UCB
4.4.8.2 Sorilux (calcipotriene foam) - GSK
4.4.8.3 Siliq (brodalumab) - AstraZeneca/ LEO Pharma
4.4.8.4 Other Psoriasis Drugs: Sales Forecast 2018-2028
4.5 Psoriasis Drugs Market: Summary
5. Skin Infection Drugs Market: Market Analysis and Forecast 2018-2028
5.1 Skin Infection Drugs: Abundant Growth Opportunities
5.1.1 Leading Products in the Skin Infection Drugs Market, 2017
5.2 Skin Infection Drugs: Market Forecast 2018-2028
5.2.1 Skin Infection: Changing Market Shares by Leading Drugs 2018-2028
5.3 Leading Drugs Used in the Treatment of Skin Infections
5.3.1 Cubicin (daptomycin) - Cubist Pharmaceuticals/ Merck & Co
5.3.2 Acquisition by Merck & Co
5.3.3 Generic Competition for Cubicin
5.3.4 Cubicin: Sales Forecast 2018-2028
5.3.5 Lifecycle Management Strategies for Cubicin
5.4 Zyvox (linezolid) - Pfizer
5.4.1 Zyvox: Historical Sales Analysis, 2010-2017
5.4.2 Zyvox: Sales Forecast 2018-2028
5.4.3 The Threats to Zyvox Sales from Competing New Drugs
5.5 Canesten (clotrimazole) - Bayer
5.5.1 Canesten: Historical Sales Analysis, 2011-2017
5.5.2 Canesten: Sales Forecast 2018-2028
5.6 Valtrex (valaciclovir) - GSK
5.6.1 Valtrex: Historical Sales Analysis, 2010-2017
5.6.2 Valtrex: Sales Forecast 2018-2028
5.7 Bactroban (mupirocin) - GSK
5.7.1 Bactroban: Historical Sales Analysis, 2010-2013
5.7.2 Bactroban: Sales Forecast 2018-2028
5.8 Lamisil (terbinafine) - Novartis
5.8.1 Lamisil Patent Expiry
5.8.2 Lamisil Sales Affected by Novartis Manufacturing Problems
5.8.3 Lamisil: Sales Forecast 2018-2028
5.9 Other Skin Infection Drugs
5.9.1 Dalvance (dalbavancin) - Durata Therapeutics
5.9.2 Jublia (efinaconazole) - Valeant
5.9.3 Kerydin (tavaborole) - Anacor
5.9.4 Sivextro (tedizolid) – Cubist Pharmaceuticals
5.9.5 Zovirax (acyclovir) - Valeant/GSK
5.9.5.1 Valeant Acquires Zovirax in US and Canada
5.9.5.2 Mylan‟s Generic Zovirax and Actavis‟ Authorised Generic
5.9.6 Other Skin Infection Drugs: Sales Forecast 2018-2028
5.10 Skin Infection Drugs: Market Summary
6. Acne Drugs Market: Market Analysis and Forecast 2018-2028
6.1 Acne Drugs: A Diversified Market
6.1.1 Leading Products in the Acne Drugs Market, 2017
6.2 Acne Drugs Market: Recent Trends and Developments
6.2.1 The Rise of Combination Therapies in Acne Treatment
6.2.2 Oral Contraceptives in Treating Acne
6.2.3 The Threat of Generic Competition in the Acne Drugs Market
6.3 Acne Drugs: Market Forecast 2018-2028
6.3.1 Acne Drugs: Changing Market Shares by Leading Drugs 2018-2028
6.4 Leading Drugs in the Acne Drugs Market
6.4.1 Epiduo (adapalene/benzoyl peroxide) – Galderma/ Nestlé Skin Health
6.4.1.1 Epiduo: Sales Forecast 2018-2028
6.4.1.2 Galderma Settlement Agreement over Generic Epiduo
6.4.1.3 Paediatric Approval for Epiduo
6.4.2 Solodyn (minocycline) - Valeant
6.4.2.1 Solodyn: Sales Forecast 2018-2028
6.4.2.2 Antitrust Action over Solodyn Pay-For-Delay Deals
6.4.2.3 Impax and Medicis Collaborating on Advanced Solodyn
6.4.2.4 Medicis and Lupin Settle
6.4.3 Claravis (isotretinoin) - Teva
6.4.3.1 Claravis: Sales Forecast 2018-2028
6.4.4 Aczone (dapsone) - Allergan
6.4.4.1 Aczone: Sales Forecast 2018-2028
6.4.5 Differin (adapalene) – Galderma/ Nestlé Skin Health
6.4.5.1 Recent Generic Competition to Differin
6.4.5.2 Differin: Sales Forecast 2018-2028
6.4.5.3 Adapalene Gel to be Available OTC in the US
6.4.5.4 Federal Circuit Court Invalidates Differin Patents
6.4.6 Absorica/Epuris (CIP-isotretinoin) – Cipher/Sun Pharma
6.4.6.1 Absorica/Epuris: Sales Forecast 2018-2028
6.4.7 Ziana (clindamycin/tretinoin) – Valeant Pharmaceuticals International
6.4.7.1 Valeant‟s Patent Settlement with Actavis over Ziana
6.4.7.2 Ziana: Sales Forecast 2018-2028
6.4.8 Doryx (doxycycline) – Actavis/Mayne Pharma
6.4.8.1 Lifecycle Management Strategies for Doryx
6.4.8.2 Divestment Agreement with Mayne Pharma
6.4.8.3 Generic Competition for Doryx
6.4.8.4 Doryx: Sales Forecast 2018-2028
6.4.9 Other Acne Drugs
6.4.9.1 Acanya (clindamycin/benzoyl peroxide) – Dow
6.4.9.1.1 Actavis Claims First-to-File Exclusivity for its Acanya
6.4.9.1.2 Legal Battles Involving Dow/Valeant, Perrigo, and Watson
6.4.9.2 Amnesteem (isotretinoin) - Mylan
6.4.9.2.1 Amnesteem: Financial Analysis
6.4.9.3 Diane (cyproterone/ethinyl estradiol) - Bayer
6.4.9.4 Duac (clindamycin/benzoyl peroxide) –
6.4.9.5 Veltin (tretinoin/clindamycin) - GSK
6.4.9.6 Other Acne Drugs: Sales Forecast 2018-2028
6.5 Acne Drugs: Market Summary
7. Dermatitis Drugs Market: Market Analysis and Forecast 2018-2028
7.1 Dermatitis Drugs: High Generic Penetration
7.1.1 Leading Products in the Dermatitis Drugs Market, 2017
7.2 Dermatitis Drugs: Market Forecast 2018-2028
7.2.1 Dermatitis Drugs: Changing Market Shares by Leading Drugs 2018-2028
7.3 Leading Drugs in the Dermatitis Drugs Market
7.3.1 Bepanthen (dexpanthenol)/ Bepanthol - Bayer
7.3.1.1 Bepanthen: Sales Forecast 2018-2028
7.3.2 Elocon (mometasone) - Merck & Co
7.3.2.1 Elocon: Sales Forecast 2018-2028
7.3.3 Protopic (tacrolimus) – LEO Pharma
7.3.3.1 Protopic Benefits from Expanded Indication
7.3.3.2 Generic Competition for Protopic
7.3.3.3 Protopic: Sales Forecast 2018-2028
7.3.4 Dermovate -GSK
7.3.4.1 Dermovate: Sales Forecast 2018-2028
7.3.5 Other Dermatitis Drugs: Sales Forecast 2018-2028
7.4 Dermatitis Drugs: Market Outlook
8. Leading National Markets 2018-2028
8.1 Geographical Breakdown of the World Dermatological Drugs Market
8.2 World Dermatological Drugs Market: Regional Forecast 2018-2028
8.2.1 How Will Regional Market Shares Change to 2028?
9. North America Dermatological Drugs Market 2018-2028
9.1. U.S. Dermatological Drugs Market: Trends and Developments
9.1.1. Obamacare Repeal
9.1.2. Legislative Environment Stimulating Biosimilars
9.1.3 Biosimilar Interchangeability guidance in the US
9.1.4 US Dermatological Drugs Market: Market Forecast 2018-2028
9.2. Canada Dermatological Drugs Market: Trends and Developments
10. Europe Dermatological Drugs Market 2018-2028
10.1 Europe Markets: Changing Market Shares by Country, 2018-2028
10.2 Germany
10.2.1 Germany Dermatological Drugs Market: Market Forecast 2018-2028
10.3. France Dermatological Drugs Market Forecast 2018-2028
10.4. U.K.
10.4.1 The Impact of Brexit On the Dermatological Drugs
10.4.2 Pricing and Reimbursement
10.4.3 New Regulatory Body and Clinical Trials
10.4.4 Patent Protection
10.4.5 Research and Funding
10.4.6. U.K. Dermatological Drugs Market Forecast 2018-2028
10.5 Italy
10.5.1 Italy Dermatological Drugs Market Forecast 2018-2028
10.6. Spain Dermatological Drugs Market Forecast 2018-2028
10.7. Rest of Europe Dermatological Drugs Market Forecast 2018-2028
10.7.1 Russia
10.7.1.1 Pharma2020 Strategy - Healthcare and Industry Reform
11. Asia-Pacific Dermatological Drugs Market 2018-2028
11.1 China
11.1.1 Expansion of Healthcare Coverage and Reimbursement in China
11.1.2 Improving Public Perception of Dermatology in China
11.1.3 Price Controls and the Anhui Model
11.1.4 Chinese Dermatological Drugs Market Forecast 2018-2028
11.2. Japan Dermatological Drugs Market: Trends and Developments
11.2.1 The Cost of Treatment in Japan
11.2.2 Japanese Pharmaceutical Industry Regulatory Reform
11.2.3 Japanese Dermatological Drugs Market Forecast
11.3. India
11.3.1 The Effects of the Drug Prices Control Order of 2013
11.3.2 India‟s Expansion of Healthcare Provision
11.3.3 Revised Biosimilar Guidelines
11.3.4 Indian Dermatological Drugs Market Forecast 2018-2028
11.4. Rest of Asia-Pacific Dermatological Drugs Market: Trends and Developments
12. Latin America Dermatological Drugs Market 2018-2028
12.1 Brazil
12.1.1 The Growth in Brazil‟s Healthcare Landscape
12.1.2 Clearer Access to Medicines in Brazil
12.1.3 Brazil Dermatological Drugs Market Forecast 2018-2028
12.2. Mexico Dermatological Drugs Market: Trends and
12.3. Rest of Latin America Dermatological Drugs Market: Trends and Developments
13. Middle East & Africa Dermatological Drugs Market 2018-2028
13.1. Saudi Arabia Dermatological Drugs Market Forecast 2018-2028
13.2. South Africa Dermatological Drugs Market Forecast 2018-2028
13.3. Rest of Middle East & Africa Dermatological Drugs Market Forecast 2018-2028
14. Leading Companies in the Dermatological Drugs Market
14.1. Galderma (Nestle Skin Health S.A.)
14.1.1 Galderma: Dermatological Drugs Product Portfolio
14.1.2 Financial Overview
14.1.3 Recent Transactions Summary
14.2. Johnson & Johnson
14.2.1 Johnson & Johnson: Dermatological Drugs Product Portfolio
14.2.2 Financial Overview
14.2.2.1 Pipeline, 2018
14.2.3 Recent Transactions Summary
14.3. GlaxoSmithKline plc
14.3.1 GlaxoSmithKline plc: Dermatological Drugs Portfolio
14.3.2 GlaxoSmithKline plc: Financial Overview
14.3.3 GlaxoSmithKline plc: Recent Transactions Summary
14.4. Pfizer, Inc.
14.4.1 Pfizer, Inc.: Dermatological Drugs Portfolio
14.4.2 Pfizer, Inc.: Financial Overview
14.4.3 Pfizer, Inc.: Recent Developments
14.4.4 Pfizer: Dermatological Drugs Development Pipeline, 2018
14.5.LEO Pharma A/S
14.5.1 LEO Pharma A/S.: Dermatological Drugs Product Portfolio
14.5.2 Financial Overview
14.5.3 Recent Transactions Summary
14.6. AbbVie Inc.
14.6.1 AbbVie Inc.: Dermatological Drugs Product Portfolio
14.6.2 Financial Overview
14.6.3 Recent Transactions Summary
14.7. Novartis AG
14.7.1 Novartis: Dermatological Drugs Portfolio
14.7.2 Novartis: Financial Overview
14.7.3 Novartis: Recent Developments
14.8. Amgen, Inc.
14.8.1 Amgen, Inc.: Dermatological drugs Portfolio
14.8.2 Financial Overview
14.8.3 Recent Transactions Summary
14.9 Merck & Co., Inc.
14.9.1 Merck & Co., Inc.: Dermatological Drugs Portfolio
14.9.2 Merck & Co., Inc.: Financial Overview
14.9.3 Merck & Co., Inc.: Recent Transactions Summary
14.10 Bayer AG
14.10.1 Bayer AG: Dermatological Drugs Portfolio
14.10.2 Bayer AG: Financial Overview
14.10.3 Bayer AG: Recent Transactions Summary
15. Dermatological Drugs: Research and Development Pipeline, 2018-2028
15.1 Innovative Products Currently in Development Will Drive Growth
15.1.1 New Technology in R&D Pipeline Activities
15.1.1.1 Reformulation
15.1.1.2 Combination Treatments
15.1.1.3 New Mechanisms and Drug Delivery Technologies
15.1.1.4 Potential Market Entrants
15.2 Psoriasis Drugs Development Pipeline, 2017
15.2.1 Psoriasis Drugs in Phase 3 Development or
15.2.1.2 CF101 (Piclidenoson) - Can-Fite BioPharma
15.2.2 Psoriasis Drugs in Phase 2 Development
15.2.2.1 LY3009104 (baricitinib) - Incyte/ Eli Lilly
15.2.2.2 PH-10 (Rose Bengal) – Provectus
15.2.3 Psoriasis Drugs in Phase 1 and Pre-Clinical
15.3 Skin Infection Drugs Development Pipeline, 2018
15.3.1 Drugs in Phase 3 Development for Skin Infections
15.3.1.1 Baxdela (delafloxacin) - Melinta Pharmaceuticals
15.3.1.2 NB-001 - NanoBio Corporation
15.3.1.3 Luliconazole - Topica Pharmaceuticals
15.3.2 Drugs in Phase 2 Development for Skin Infections
15.3.3 Drugs in Phase 1 and Preclinical Pipeline for Skin Infections
15.4 Acne Drugs Development Pipeline, 2017
15.4.1 Drugs in Phase 3 Development for Acne
15.4.1.2 Visonac (photodynamic therapy) - Photocure
15.4.2 Drugs in Phase 2 Development for Acne
15.4.3 Drugs in Phase 1 and Pre-Clinical Development for Acne
15.4.4 A Possible Vaccine for Acne
15.5 Dermatitis Drugs Development Pipeline, 2017
15.5.1 Drugs in Phase 3 Development for Dermatitis
15.5.1.1 Toctino (alitretinoin) - GSK
15.5.1.2 Dermadexin and Pruridexin (P3CGM) – Cipher
15.5.1.3 Dexeryl Cream (glycerol/paraffin emollient) – Pierre
15.5.1.4 REGN668/SAR231893 (dupilumab) -
15.5.2 Drugs in Phase 2 Development for Dermatitis
15.5.3 Drugs in Phase 1 and Preclinical Stages of Development for Dermatitis
15.6 Other Dermatological Drugs Development Pipeline, 2017
15.6.1 Other Dermatological Drugs: Filed or Recently
15.6.1.1 Actikerall (fluorouracil/salicylic acid) - Almirall
15.6.1.2 Ameluz (5-ALA photodynamic therapy) - Biofrontera
15.6.1.3 Mirvaso (brimonidine) - Galderma
15.6.1.4 Picato (ingenol mebutate) - LEO Pharma
15.6.1.5 Xolair (omalizumab) - Novartis/ Roche
15.6.2 Other Dermatological Drugs: Phase 3 Pipeline
15.6.2.1 CD5024 (ivermectin) - Galderma
15.6.2.2 SR-T100 gel (Solanum incanum extract) - G&E
15.6.3 Other Dermatological Drugs: Phase 2 Pipeline
16. Qualitative Analysis of the Dermatological Drugs Market, 2018-2028
16.1 Market Factors Influencing Dermatological Drugs
16.2 SWOT Analysis of the Global Dermatological Drugs Market, 2018-2028
16.2.1 Strengths
16.2.1.1 The High Unmet Clinical Need in Dermatology
16.2.1.2 A Healthy Pipeline of Development-Stage Products
16.2.1.3 Strong Industry-Physician Relationships
16.2.2 Weaknesses
16.2.2.1 Limited Efficacy and Adverse Effects May Impact
16.2.2.2 Patient Adherence – A Major Challenge to
16.2.2.3 Impending Patent Expiries and the Challenges
16.2.3 Opportunities
16.2.3.1 The High-Growth Sectors in Dermatology
16.2.3.2 Personalised Dermatology: Technological Advances in Genomics
16.2.3.3 Advances in Topical Drug Delivery Methods Offers
16.2.3.4 Consolidation within Dermatology – Opportunity for Synergistic Growth?
16.2.4 Threats
16.2.4.1 Uncertainty Surrounding Reimbursement and
16.2.4.2 The Rising Cost of Research and Development
16.2.4.3 Downward Pressures on Drug Prices
16.3 Porter’s Five Force Analysis of the Global Dermatological Drugs Market, 2018-2028
16.3.1 Threat of New Entrants
16.3.2 Threat of Substitutes
16.3.3 Rivalry among Competitors
16.3.4 Power of Buyers
16.3.5 Power of Suppliers
17. Conclusions
17.1 Overview of Current Market Conditions and Market Forecast, 2018-2028
17.2 Leading Sectors in Dermatological Drugs in 2017
17.3 Leading Regions in the Dermatological Drugs Market in 2017
17.4 Future Outlook for the Various Sectors within the Dermatological Drugs Market, 2018-2028
17.5 What Does the Future Hold for Dermatological Drugs?
Appendices
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form
List of Tables
Table 2.1 Clinical Trial Phases, 2017
Table 3.1 Global Dermatological Drugs Market by Drugs Class: Revenue ($bn), and Market Share (%), 2017
Table 3.2 Global Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
Table 3.3 Global Dermatological Drugs Market by Drugs Class: CAGR (%), 2018-2022, 2022-2028, 2018-2028
Table 4.1 Global Psoriasis Drugs Market by Drugs Class: Revenue ($bn), and Market Share (%), 2017
Table 4.2 Global Psoriasis Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
Table 4.3 Global Psoriasis Drugs Market by Drugs Class: CAGR (%), 2018-2022, 2022-2028, 2018-2028
Table 4.4 Global Humira Market Forecast: Revenues ($bn) AGR (%), 2010-2017
Table 4.5 Global Humira Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 4.6 Global Stelara Market Forecast: Revenues ($bn) AGR (%), 2010-2017
Table 4.7 Global Stelara Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 4.8 Global Enbrel Market Forecast: Revenues ($Bn) AGR (%), 2009-2017
Table 4.9 Global Enbrel Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 4.10 Global Remicade Market Forecast: Revenues ($bn) AGR (%), 2009-2017
Table 4.11 Global Remicade Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 4.12 Global Taltz Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 4.13 Global Otezla Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 4.14 Global Cosentyx Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 4.15 Global Others Market Forecast: Revenues ($Bn) AGR (%), CAGR (%), 2016-2028
Table 5.1 Global Skin Infection Drugs Market by Drugs Class: Revenue ($bn), and Market Share (%), 2017
Table 5.2 Skin Infection Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
Table 5.3 Global Skin Infection Drugs Market by Drugs Class: CAGR (%), 2018-2022, 2022-2028, 2018-2028
Table 5.4 Global Cubicin Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 5.5 Global Zyvox Market Forecast: Revenues ($bn) AGR (%), 2010-2017
Table 5.6 Global Zyvox Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 5.7 Global Canesten Market Forecast: Revenues ($bn) AGR (%), 2011-2017
Table 5.8 Global Canesten Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 5.9: Global Valtrex Market Forecast: Revenues ($bn) AGR (%), 2010-2017
Table 5.10 Global Valtrex Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 5.11 Global Bactroban Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 5.12 Global Lamisil Market Forecast: Revenues ($Bn) AGR (%), CAGR (%), 2016-2028
Table 5.13 Global Others Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 6.1 Global Acne Drugs Market by Drugs Class: Revenue ($bn), and Market Share (%), 2017
Table 6.2 Global Acne Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
Table 6.3 Global Acne Drugs Market by Drugs Class: CAGR (%), 2018-2022, 2022-2028, 2018-2028
Table 6.4 Global Epiduo Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 6.5 Global Solodyn Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 6.6 Global Claravis Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 6.7 Global Aczone Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 6.8 Global Differin Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 6.9 Global Absorica/ Epirus Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 6.10 Global Ziana Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 6.11 Global Doryx Market Forecast: Revenues ($Bn) AGR (%), CAGR (%), 2016-2028
Table 6.12 Global Others Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 7.1 Global Dermatitis Drugs Market by Drugs Class: Revenue ($bn), and Market Share (%), 2017
Table 7.2 Global Dermatitis Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
Table 7.3 Global Dermatitis Drugs Market by Drugs Class: CAGR (%), 2018-2022, 2022-2028, 2018-2028
Table 7.4 Global Bepanthen/ Bepanthol Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 7.5 Global Elocon Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 7.6 Global Protopic Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 7.7 Global Dermovate Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 7.8 Others Dermatitis Drugs Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
Table 8.1 Global Dermatological Drugs Market by Region: Revenue ($bn), 2016 and 2017
Table 8.2 Global Dermatological Drugs Market Forecast, by Region: Revenues ($ bn), AGR (%), CAGR (%), 2016-2028
Table 8.3 Global Dermatological Drugs Market by Region: CAGR (%), 2018-2022, 2022-2028, 2018-2028
Table 8.4 Global Dermatological Drugs Market by Region: CAGR (%), 2018-2022, 2022-2028, 2018-2028
Table 9.1 North America Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
Table 9.2 North America Dermatological Drugs Market Forecast, By Country: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
Table 9.3 U.S. Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
Table 9.4 Canada Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
Table 10.1 Global Dermatological Drugs Market by Country/Sub-region: Revenue ($bn) and Market Share (%), 2017
Table 10.2 Europe Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
Table 10.3 Europe Dermatological Drugs Market Forecast, By Country: Revenues ($ bn), AGR (%), CAGR (%), 2016-2028
Table 10.4 Europe Dermatological Drugs Market by Country/Sub-region: CAGR (%), 2018-2022, 2022-2028, 2018-2028
Table 10.5 Germany Dermatological Drugs Market Forecast, 2016-2028 ($bn, AGR %, CAGR %)
Table 10.6 France Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
Table 10.7 U.K. Dermatological Drugs Market Forecast, 2016-2028 ($bn, AGR %, CAGR %)
Table 10.8 Italy Dermatological Drugs Market Forecast, 2016-2028 ($bn, AGR %, CAGR %)
Table 10.9 Spain Dermatological Drugs Market Forecast, 2016-2028 ($bn, AGR %, CAGR %)
Table 10.10 Rest of Europe Dermatological Drugs Market Forecast, 2016-2028 ($bn, AGR %, CAGR %)
Table 11.1 Asia-Pacific Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
Table 11.2 Asia-Pacific Dermatological Drugs Market Forecast, By Country: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
Table 11.3 China Dermatological Drugs Market Forecast, 2016-2028 ($bn, AGR %, CAGR %)
Table 11.4 Japan Dermatological Drugs Market Forecast, 2016-2028 ($bn, AGR %, CAGR %)
Table 11.5 India Dermatological Drugs Market Forecast, 2016-2028 ($bn, AGR %, CAGR %)
Table 11.6 Rest of Asia-Pacific Dermatological Drugs Market Forecast, 2016-2028 ($ bn, AGR %, CAGR %)
Table 12.1 Latin America Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
Table 12.2 Latin America Dermatological Drugs Market Forecast, By Country: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
Table 12.3 Brazil Dermatological Drugs Market Forecast, 2016-2028 ($bn, AGR %, CAGR %)
Table 12.4 Mexico Dermatological Drugs Market Forecast, 2016-2028 ($bn, AGR %, CAGR %)
Table 12.5 Rest of Latin America Dermatological Drugs Market Forecast, 2016-2028 ($bn, AGR %, CAGR %)
Table 13.1 Middle East & Africa (MEA) Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
Table 13.2 Middle East & Africa (MEA) Dermatological Drugs Market Forecast, By Country: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
Table 13.3 Saudi Arabia Dermatological Drugs Market Forecast, By Country: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
Table 13.4 South Africa Dermatological Drugs Market Forecast, 2016-2028 ($bn, AGR %, CAGR %)
Table 13.5 Rest of MEA Dermatological Drugs Market Forecast, 2016-2028 ($bn, AGR %, CAGR %)
Table 14.1 Galderma: Overview, 2018
Table 14.2 Nestle: Revenue ($m), AGR (%), 2013-2017
Table 14.3. Johnson & Johnson: Overview, 2018
Table 14.4 Johnson & Johnson: Revenue ($m), AGR (%), 2013-2017
Table 14.5 GlaxoSmithKline plc: Overview, 2018
Table 14.6 GlaxoSmithKline plc: Revenue ($m), AGR (%), 2013-2017
Table 14.7 GlaxoSmithKline: Dermatological Drugs Pipeline, 2018
Table 14.8 Pfizer, Inc.: Overview, 2018
Table 14.9 Pfizer, Inc.: Revenue ($m), AGR (%), 2013-2017
Table 14.10 LEO Pharma A/S: Overview, 2018
Table 14.11 LEO Pharma A/S: Revenue ($m), AGR (%), 2013-2017
Table 14.12 AbbVie Inc.: Overview, 2018
Table 14.13 AbbVie Inc.: Revenue ($m), AGR (%), 2013-2017
Table 14.14 Novartis: Overview, 2018
Table 14.15 Novartis: Revenue ($m), AGR (%), 2013-2017
Table 14.16 Amgen, Inc.: Overview, 2018
Table 14.17 Amgen, Inc.: Revenue ($m), AGR (%), 2013-2017
Table 14.18 Merck & Co., Inc.: Overview, 2018
Table 14.19 Merck & Co., Inc.: Revenue ($m), AGR (%), 2013-2017
Table 14.20 Bayer AG: Overview, 2018
Table 14.21 Bayer AG: Revenue ($m), AGR (%), 2013-2017
Table 15.1 Psoriasis Drugs Pipeline: Phase 3 Drugs, 2018
Table 15.2 Psoriasis Drugs Pipeline: Phase 2 Drugs, 2018
Table 15.3 Psoriasis Drugs Pipeline: Phase 1 Drugs, 2018
Table 15.4 Skin Infections Drugs Pipeline: Phase 3 Drugs, 2018
Table 15.5 Skin Infections Drugs Pipeline: Phase 2 Drugs, 2018
Table 15.6 Acne Drugs Pipeline: Phase 3 Drugs, 2018
Table 15.7 Acne Drugs Pipeline: Phase 2 Drugs, 2018
Table 15.8 Dermatitis Drugs Pipeline: Phase 3 Drugs, 2018
Table 15.9 Dermatitis Drugs Pipeline: Phase 2 Drugs, 2018
Table 15.10 Other Dermatological Drugs Pipeline: Filed or Recently Launched Drugs, 2016
Table 15.11 Other Dermatological Drugs Pipeline: Phase 3 Drugs, 2018
Table 15.12 Dermatitis Drugs Pipeline: Phase 2 Drugs, 2018
Table 16.1 SWOT Analysis of the Global Dermatological Drugs Market, 2018-2028
Table 17.1 Global Dermatological Drugs Market Forecast: Revenue ($bn), and CAGR (%), 2017, 2022 and 2028
Table 17.2 Global Dermatological Drugs Market by Drugs Class: Revenue ($bn), and Market Share (%), 2017
Table 17.3 Global Dermatological Drugs Market by Region: Revenue ($bn), 2016, 2022, 2028
Table 17.4 Global Dermatological Drugs Market by Drug Class: CAGR (%), 2017, 2022, 2028
List of Figures
Figure 1.1 Global Dermatological Drugs Market Segmentation Overview
Figure 2.1 Anatomy of Human Skin
Figure 3.1 Global Dermatological Drugs Market by Drugs Class: Market Share (%), 2017
Figure 3.2 World Dermatological Drugs Market: Revenues ($bn), by Drugs Class, 2017
Figure 3.3 Global Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%), 2016-2028
Figure 3.4 The Global Dermatological Drugs Market Forecast by Sector: CAGR (%), 2018-2022
Figure 3.5 The Global Dermatological Drugs Market Forecast by Sector: CAGR (%), 2022-2028
Figure 3.6 The Global Dermatological Drugs Market Forecast by Sector: CAGR (%), 2018-2028
Figure 3.7 Global Dermatological Drugs Market by Drugs Class: Market Share (%), 2017
Figure 3.8 Global Dermatological Drugs Market by Drugs Class: Market Share (%), 2022
Figure 3.9 Global Dermatological Drugs Market by Drugs Class: Market Share (%), 2028
Figure 4.1 World Psoriasis Drugs Market: Revenues ($bn), by Drugs Class, 2017
Figure 4.2 Global Psoriasis Drugs Segment Forecast: Revenue ($bn) AGR (%), 2016-2028
Figure 4.3 Global Psoriasis Drugs Market by Leading Drugs: Market Share (%), 2017
Figure 4.4 Global Psoriasis Drugs Market by Leading Drugs: Market Share (%), 2022
Figure 4.5 Global Psoriasis Drugs Market by Leading Drugs: Market Share (%), 2028
Figure 4.6 Global Humira Market Forecast: Revenue ($bn) AGR (%), 2010-2017
Figure 4.7 Global Humira Market Forecast: Revenue ($bn) AGR (%), 2016-2028
Figure 4.8 Global Stelara Market Forecast: Revenue ($bn) AGR (%), 2010-2017
Figure 4.9 Global Stelara Market Forecast: Revenue ($bn) AGR (%), 2016-2028
Figure 4.10 Global Enbrel Market Forecast: Revenue ($bn) AGR (%), 2009-2017
Figure 4.11 Global Enbrel Market Forecast: Revenue ($bn) AGR (%), 2016-2028
Figure 4.12 Global Remicade Market Forecast: Revenue ($bn) AGR (%), 2009-2017
Figure 4.13 Global Remicade Market Forecast: Revenue ($bn) AGR (%), 2016-2028
Figure 4.14 Global Taltz Market Forecast: Revenue ($bn) AGR (%), 2016-2028
Figure 4.15 Global Otezla Market Forecast: Revenue ($bn) AGR (%), 2016-2028
Figure 4.16 Global Cosentyx Market Forecast: Revenue ($bn) AGR (%), 2016-2028
Figure 4.17 Global Others Market Forecast: Revenue ($bn) AGR (%), 2016-2028
Figure 5.1 World Skin Infection Drugs Market: Revenues ($bn), by Drugs Class, 2017
Figure 5.2 Global Skin Infection Drugs Segment Forecast: Revenue ($bn) AGR (%), 2016-2028
Figure 5.3 The Skin Infection Drugs Market by Leading Drugs: Market Share (%), 2017
Figure 5.4 The Skin Infection Drugs Market by Leading Drugs: Market Share (%), 2022
Figure 5.5 The Skin Infection Drugs Market by Leading Drugs: Market Share (%), 2028
Figure 5.6 Global Cubicin Market Forecast: Revenue ($bn) AGR (%), 2016-2028
Figure 5.7 Global Zyvox Market Forecast: Revenue ($bn) AGR (%), 2010-2017
Figure 5.8 Global Zyvox Market Forecast: Revenue ($bn) AGR (%), 2016-2028
Figure 5.9 Global Canesten Market Forecast: Revenue ($bn) AGR (%), 2011-2017
Figure 5.10 Global Canesten Market Forecast: Revenue ($Bn) AGR (%), 2016-2028
Figure 5.11 Global Valtrex Market Forecast: Revenue ($bn) AGR (%), 2010-2017
Figure 5.12 Global Valtrex Market Forecast: Revenue ($bn) AGR (%), 2016-2028
Figure 5.13 Global Bactroban Market Forecast: Revenue ($bn) AGR (%), 2016-2028
Figure 5.14 Global Lamisil Market Forecast: Revenue ($bn) AGR (%), 2016-2028
Figure 5.15 Global Others Market Forecast: Revenue ($bn) AGR (%), 2016-2028
Figure 6.1 World Acne Drugs Market: Revenues ($bn), by Drugs Class, 2017
Figure 6.2 Global Acne Drugs Segment Forecast: Revenue ($bn) AGR (%), 2016-2028
Figure 6.3 The Global Acne Drugs Market by Leading Drugs: Market Share (%), 2017
Figure 6.4 The Global Acne Drugs Market by Leading Drugs: Market Share (%), 2022
Figure 6.5 The Global Acne Drugs Market by Leading Drugs: Market Share (%), 2028
Figure 6.6 Global Epiduo Market Forecast: Revenue ($bn) AGR (%), 2016-2028
Figure 6.7 Global Solodyn Market Forecast: Revenue ($bn) AGR (%), 2016-2028
Figure 6.8 Global Claravis Market Forecast: Revenue ($bn) AGR (%), 2016-2028
Figure 6.9 Global Aczone Market Forecast: Revenue ($bn) AGR (%), 2016-2028
Figure 6.10 Global Differin Market Forecast: Revenue ($bn) AGR (%), 2016-2028
Figure 6.11 Global Absorica/ Epirus Market Forecast: Revenue ($bn) AGR (%), 2016-2028
Figure 6.12 Global Ziana Market Forecast: Revenue ($bn) AGR (%), 2016-2023
Figure 6.13 Global Doryx Market Forecast: Revenue ($bn) AGR (%), 2016-2028
Figure 6.14 Global Others Market Forecast: Revenue ($bn) AGR (%), 2016-2028
Figure 7.1 World Dermatitis Drugs Market: Revenues ($bn), by Drugs Class, 2017
Figure 7.2 Global Dermatitis Drugs Segment Forecast: Revenue ($bn) AGR (%), 2016-2028
Figure 7.3 The Global Dermatitis Drugs Market by Leading Drugs: Market Share (%), 2017
Figure 7.4 The Global Dermatitis Drugs Market by Leading Drugs: Market Share (%), 2022
Figure 7.5 The Global Dermatitis Drugs Market by Leading Drugs: Market Share (%), 2028
Figure 7.6 Global Bepanthen/ Bepanthol Market Forecast: Revenue ($bn), AGR (%), 2016-2028
Figure 7.7 Global Elocon Market Forecast: Revenue ($bn) AGR (%), 2016-2028
Figure 7.8 Global Protopic Market Forecast: Revenue ($bn) AGR (%), 2016-2028
Figure 7.9 Global Dermovate Market Forecast: Revenue ($bn) AGR (%), 2016-2028
Figure 7.10 Global Other Dermatitis Market Forecast: Revenue ($bn) AGR (%), 2016-2028
Figure 8.1 World Dermatological Drugs Market: Revenues ($bn) by Region, 2016
Figure 8.2 World Dermatological Drugs Market: Revenues ($bn) by Region, 2017
Figure 8.3 Global Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%), 2016-2028
Figure 8.4 World Dermatological Drugs Market: Market Shares (%) by Regional Market, 2017
Figure 8.5 World Dermatological Drugs Market: Market Shares (%) by Regional Market, 2022
Figure 8.6 World Dermatological Drugs Market: Market Shares (%) by Regional Market, 2028
Figure 9.1 North America Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2016-2028
Figure 9.2 North America Dermatological Drugs Market: Market Shares (%) by Country, 2017
Figure 9.3 North America Dermatological Drugs Market: Market Shares (%) by Country, 2022
Figure 9.4 North America Dermatological Drugs Market: Market Shares (%) by Country, 2028
Figure 9.5 U.S. Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2016-2028
Figure 9.6 Canada Dermatological Drugs Market Forecast: Revenues ($ Bn), AGR (%), 2016-2028
Figure 10.1 Europe Dermatological Drugs Market: Revenues ($bn) by Country/Sub-region, 2017
Figure 10.2 Europe Dermatological Drugs Market Forecast: Revenues ($ bn), AGR (%), 2016-2028
Figure 10.3 Europe Dermatological Drugs Market: Market Shares (%) by Regional Market, 2017
Figure 10.4 Europe Dermatological Drugs Market: Market Shares (%) by Country Market, 2022
Figure 10.5 Europe Dermatological Drugs Market: Market Shares (%) by Country Market, 2028
Figure 10.6 Germany Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2016-2028
Figure 10.7 France Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2016-2028
Figure 10.8 U.K. Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2016-2028
Figure 10.9 Italy Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2016-2028
Figure 10.10 Spain Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2016-2028
Figure 10.11 Rest of Europe Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2016-2028
Figure 11.1 Asia-Pacific Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2016-2028
Figure 11.2 Asia-Pacific Dermatological Drugs Market: Market Shares (%) by Country, 2017
Figure 11.3 Asia-Pacific Dermatological Drugs Market: Market Shares (%) by Country, 2022
Figure 11.4 Asia-Pacific Dermatological Drugs Market: Market Shares (%) by Country, 2028
Figure 11.5 China Dermatological Drugs Market Forecast: Revenues ($ bn), AGR (%), 2016-2028
Figure 11.6 Japan Dermatological Drugs Market Forecast: Revenues ($ bn), AGR (%), 2016-2028
Figure 11.7 India Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2016-2028
Figure 11.8 Rest of Asia-Pacific Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2016-2028
Figure 12.1 Latin America Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2016-2028
Figure 12.2 Latin America Dermatological Drugs Market: Market Shares (%) by Country Market, 2017
Figure 12.3 Latin America Dermatological Drugs Market: Market Shares (%) by Country Market, 2022
Figure 12.4 Latin America Dermatological Drugs Market: Market Shares (%) by Country Market, 2028
Figure 12.5 Brazil Dermatological Drugs Market Forecast: Revenues ($ bn), AGR (%), 2016-2028
Figure 12.6 Mexico Dermatological Drugs Market Forecast: Revenues ($ bn), AGR (%), 2016-2028
Figure 12.7 Rest of Latin America Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2016-2028
Figure 13.1 Middle East & Africa (MEA) Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2016-2028
Figure 13.2 Middle East & Africa Dermatological Drugs Market: Market Shares (%) by Country Market, 2017
Figure 13.3 Middle East & Africa Dermatological Drugs Market: Market Shares (%) by Country Market, 2022
Figure 13.4 Middle East & Africa Dermatological Drugs Market: Market Shares (%) by Country Market, 2028
Figure 13.5 Saudi Arabia Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2016-2028
Figure 13.6 South Africa Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2016-2028
Figure 13.7 Rest of MEA Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2016-2028
Figure 14.1 Nestle: Revenue ($m), AGR (%), 2013-2017
Figure 14.2 Nestle: Business Segment Revenue Share (%), 2017
Figure 14.3 Nestle: Region Revenue Share (%), 2017
Figure 14.4 Johnson & Johnson: Revenue ($m), AGR (%), 2013-2017
Figure 14.5 Johnson & Johnson: Business Segment Revenue Share (%), 2017
Figure 14.6 Johnson & Johnson: Region Revenue Share (%), 2017
Figure 14.7 GlaxoSmithKline plc: Revenue ($m), AGR (%), 2013-2017
Figure 14.8 GlaxoSmithKline plc: Business Segment Revenue Share (%), 2017
Figure 14.9 GlaxoSmithKline plc: Pharmaceutical Business Segment Revenue Share (%), 2017
Figure 14.10 GlaxoSmithKline plc: by Region Revenue Share (%), 2017
Figure 14.11 Pfizer, Inc.: Revenue ($m), AGR (%), 2013-2017
Figure 14.12 Pfizer, Inc.: Business Segment Revenue Share (%), 2017
Figure 14.13 Pfizer, Inc.: National Revenue Share (%), 2017
Figure 14.14 LEO Pharma A/S : Revenue ($m), AGR (%), 2013-2017
Figure 14.15 LEO Pharma A/S: Therapeutic Area Revenue Share (%), 2017
Figure 14.16 LEO Pharma A/S: Region Revenue Share (%), 2017
Figure 14.17 AbbVie Inc.: Revenue ($m), AGR (%), 2013-2017
Figure 14.18 AbbVie Inc.: Bussiness Segment Revenue Share (%), 2017
Figure 14.19 Novartis: Revenue ($m), AGR (%), 2013-2017
Figure 14.20 Novartis: Revenue, by Division, Share (%), 2017
Figure 14.21 Novartis: Revenue, by Region, Share (%), 2017
Figure 14.22 Amgen, Inc.: Revenue ($m), AGR (%), 2013-2017
Figure 14.23 Amgen, Inc.: Revenue, by Division, Share (%), 2017
Figure 14.24 Amgen, Inc.: Revenue, by Region, Share (%), 2017
Figure 14.25 Merck & Co., Inc.: Revenue ($m), AGR (%), 2013-2017
Figure 14.26 Merck & Co., Inc.: Business Segment Revenue Share (%), 2017
Figure 14.27 Merck & Co., Inc.: Region Revenue Share (%), 2017
Figure 14.28 Bayer AG: Revenue ($m), AGR (%), 2013-2017
Figure 14.29 Bayer AG: Business Segment Revenue Share (%), 2017
Figure 14.30 Bayer AG: Region Revenue Share (%), 2017
Figure 16.1 Porter‟s Five Force Analysis
Figure 17.1 Global Dermatological Drugs Market Forecast: Revenue ($bn) 2017, 2022, 2028
Figure 17.2 World Dermatological Drugs Market: Revenues ($bn), by Drugs Class, 2017
Figure 17.3 The Global Dermatological Drugs Market Forecast by Region: Revenue ($bn), 2017, 2022, 2028
Figure 17.4 The Global Dermatological Drugs Market Forecast by Region: Revenue ($bn), 2017, 2022, 2028
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
